Abstract
Microorganisms benefit and enable humans to live but also threaten the life of immunocompromised patients. In this chapter, a brief background of fungal infections along with a description of the most common antifungal agents used in the clinics is given. The text, however, focuses on the recent development in engineering yeasts to overcome fungal infections and how it can help against the antifungal resistance that is spreading throughout the world. Beyond that, this work will display what scientists have been investigating and discovering about the relation between antimicrobial resistance to antifungal agents and the pathogen’s genomes and how it could be feasible to change the current settings and optimize the therapy to save lives.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Abdel-Rahman S, Nahata M (1997) Oral Terbinafine: a new antifungal agent. Ann Pharmacother 31:445–456
Accoceberry I, Rougeron A, Biteau N, Chevrel P, Fitton-Ouhabi V, Noël T (2018) A CTG clade Candida yeast genetically engineered for the genotype-phenotype characterization of azole antifungal resistance in human-pathogenic yeasts. Antimicrob Agents Chemother 62:1–14
Alangaden GJ (2011) Nosocomial fungal infections: epidemiology, infection control, and prevention. Infect Dis Clin N Am 30:201–225. https://doi.org/10.1016/j.idc.2010.11.003
Aminov R (2017) History of antimicrobial drug discovery: major classes and health impact. Biochem Pharmacol 133:4–19. https://doi.org/10.1016/j.bcp.2016.10.001
Anderson JB (2005) Evolution of antifungal-drug resistance: mechanisms and pathogen fitness. Nat Rev Microbiol 3:547–556
Antinori S, Milazzo L, Sollima S, Galli M, Corbellino M (2016) Candidemia and invasive candidiasis in adults: a narrative review. Eur J Intern Med 34:21–28. https://doi.org/10.1016/j.ejim.2016.06.029
Arendrup MC, Fuursted K, Gahrn-Hansen B, Jensen IM, Knudsen JD et al (2005) Seminational surveillance of fungemia in Denmark: notably high rates of fungemia and numbers of isolates with reduced azole susceptibility. J Clin Microbiol 43:4434–4440
Arendrup MC, Fuursted K, Gahrn-Hansen B, Schønheyder HC, Knudsen JD et al (2008) Semi-national surveillance of fungaemia in Denmark 2004-2006: increasing incidence of fungaemia and numbers of isolates with reduced azole susceptibility. Clin Microbiol Infect 14:487–494
Benedict K, Richardson M, Vallabhaneni S, Jackson BR, Chiller T (2017) Emerging issues, challenges, and changing epidemiology of fungal disease outbreaks. Lancet Infect Dis 17:e403–e411. https://doi.org/10.1016/S1473-3099(17)30443-7
Brown GD, Denning DW, Gow NA, Levitz SM, Netea MG, White TC (2012) Hidden killers: human fungal infections. Science 4:1–10
Carmona EM, Limper AH (2017) Overview of treatment approaches for fungal infections. Clin Chest Med 38:393–402
Choi JK, Cho SY, Yoon SS, Moon JH, Kim SH et al (2017) Epidemiology and risk factors for invasive fungal diseases among allogeneic hematopoietic stem cell transplant recipients in Korea: results of ‘RISK’ study. Biol Blood Marrow Transplant 23:1773–1779. https://doi.org/10.1016/j.bbmt.2017.06.012
de Backe MD, van Dijck P (2003) Progress in functional genomics approaches to antifungal drug target discovery. Trends Microbiol 11:470–478
Denning DW (2003) Echinocandin antifungal drugs. Lancet 362:1142–1151
Denning DW, Bromley MJ (2015) How to bolster the antifungal pipeline. Science 347:1–4
Dismukes WE (2000) Introduction to antifungal drugs. Clin Infect Dis 30:653–657. https://doi.org/10.1086/313748
Enkler L, Richer D, Marchand AL, Ferrandon D, Jossinet F (2016) Genome engineering in the yeast pathogen Candida glabrata using the CRISPR-Cas9 system. Sci Rep 6:1–12. https://doi.org/10.1038/srep35766
Fisher MC, Nichola JH, Sanglard D, Gurr SJ (2018) Worldwide emergence of resistance to antifungal drugs challenges human health and food security. Science 360:739–742
Flowers SA, Colón B, Whaley SG, Schuler MA, Rogers PD (2015) Contribution of clinically derived mutations in ERG11 to azole resistance in Candida albicans. Antimicrob Agents Chemother 59:450–460
Gangneux JP, Bougnoux ME, Hennequin C, Godet C, Chandenier J et al (2016) Estimation du poids épidémiologique des infections fongiques graves en France. J Mycol Med 26:385–390. https://doi.org/10.1016/j.mycmed.2016.11.001
Gonçalves SS, Souza ACR, Chowdhary A, Meis JF, Colombo AL (2016) Epidemiology and molecular mechanisms of antifungal resistance in and. Mycoses 59(4):198–219
Gugnani HC, Denning DW (2016) Burden of serious fungal infections in the Dominican Republic. J Infect Public Health 9:7–12. https://doi.org/10.1016/j.jiph.2015.04.026
Guimarães LF, Halpern M, de Lemos AS, de Gouvêa EF, Gonçalves RT et al (2016) Invasive fungal disease in renal transplant recipients at a Brazilian center: local epidemiology matters. Transplant Proc 48:2306–2309. https://doi.org/10.1016/j.transproceed.2016.06.019
Havlickova B, Viktor AC, Friedrich M (2009) Epidemiological trends in skin mycoses worldwide. Mycoses 4:2–15
Hesstvedt L, Gaustad P, Andersen CT, Haarr E, Hannula R et al (2015) Twenty-two years of candidaemia surveillance: results from a Norwegian national study. Clin Microbiol Infect 21:938–945. https://doi.org/10.1016/j.cmi.2015.06.008
Kabir V, Maertens J, Kuypers D (2018) Fungal infections in solid organ transplantation: an update on diagnosis and treatment. Transplant Rev 33:77–86
Kartsonis NA, Nielsen J, Douglas CM (2003) Caspofungin: the first in a new class of antifungal agents. Drug Resist Updat 6:197–218. https://doi.org/10.1016/S1368-7646(03)00064
Kontoyiannis DP, Lewis RE (2017) Antifungal resistance: an emerging reality and a global challenge. J Infect Dis 216:S431–S435
Kronstad JW, Attarian R, Cadieux B, Choi J, D’Souza CA, Griffiths EJ, Geddes JM et al (2011) Expanding fungal pathogenesis: Cryptococcus breaks out of the opportunistic box. Nat Rev Microbiol 9:193–203. https://doi.org/10.1038/nrmicro2522
Lacroix C, Dubach M, Feuilhade M (2003) Les Échinocandines: une nouvelle classe d’antifongiques. Med Mal Infect 33:183–191
Lanternier F, Lortholary O (2008) Liposomal amphotericin B: what is its role in 2008? Clin Microbiol Infect 14:71–83. https://doi.org/10.1111/j.1469-0691.2008.01984
Lausch KR, Lausch KR, Søgaard M, Rosenvinge FS, Johansen HK et al (2018) High incidence of candidaemia in a nationwide cohort : underlying diseases, risk factors and mortality. Inter J Infect Dis 76:58–63. https://doi.org/10.1016/j.ijid.2018.08.010
Lelièvre L, Groh M, Angebault C, Maherault AC, Didier E, Bougnoux ME (2013) Azole resistant Aspergillus fumigatus: an emerging problem. Med Mal Infect 43:139–145. https://doi.org/10.1016/j.medmal.2013.02.010
Maertens JA (2004) History of the development of azole derivatives. Clin Microbiol Infect 10:1–10
Maertens JA, Boogaerts M (2003) Review caspofungin in the treatment of candidosis and aspergillosis. Int J Infect Dis 7:94–101
Mahmoudi R, Zafarghandi MS, Abbasabadi B, Tavallaee M (2011) The epidemiology of Candida species associated with vulvovaginal candidiasis in an Iranian patient population. Eur J Obstet Gynecol Reprod Biol 155:199–203. https://doi.org/10.1016/j.ejogrb.2010.11.022
Małek M, Paluchowska P, Bogusz B, Budak A (2017) Caracterización molecular de aislamientos de Candida de pacientes en cuidados intensivos en Cracovia, Polonia. Rev Iberoam Micol 34:10–16
Marichal P, Koymans L, Willemsens S, Bellens D, Verhasselt P et al (1999) Contribution of mutations in the cytochrome azole resistance in Candida albicans. Microbiology 145:2701–2713
Matzaraki V, Gresnigt MS, Jaeger M, Ricaño-Ponce I, Johnson MD et al (2017) An integrative genomics approach identifies novel pathways that influence candidaemia susceptibility. PLoS One 12:1–18
Moghnieh R, Alothman AF, Althaqafi AO, Matar MJ, Alenazi TH et al (2017) Epidemiology and outcome of invasive fungal infections and methicillin-resistant Staphylococcus aureus (MRSA) pneumonia and complicated skin and soft tissue infections (CSSTI) in Lebanon and Saudi Arabia. J Infect Public Health 10:849–854. https://doi.org/10.1016/j.jiph.2017.01.013
Morace G, Perdoni F, Borghi E (2014) Antifungal drug resistance in Candida species. J Glob Antimicrob Resist 2:254–259. https://doi.org/10.1016/j.jgar.2014.09.002
Morio F, Loge C, Besse B, Hennequin C, Le Pape P et al (2010) Screening for amino acid substitutions in the Candida albicans Erg11 protein of azole-susceptible and azole-resistant clinical isolates: new substitutions and a review of the literature. Diagn Microbiol Infect Dis 66:373–384. https://doi.org/10.1016/j.diagmicrobio.2009.11.006
Nailor MD, Sobel JD (2006) Progress in antifungal therapy: echinocandins versus azoles. Drug Discov Today Ther Strateg 3:221–226
Nicola AM, Albuquerque P, Paes HC, Fernandes L, Costa FF et al (2018) Antifungal drugs: new insights in research & development. Pharmacol Ther 195:21–38. https://doi.org/10.1016/j.pharmthera.2018.10.008
Nieto MC, Tellería O, Cisterna R (2015) Sentinel surveillance of invasive candidiasis in Spain: epidemiology and antifungal susceptibility. Diagn Microbiol Infect Dis 81:34–40. https://doi.org/10.1016/j.diagmicrobio.2014.05.021
Noël T (2012) The cellular and molecular defense mechanisms of the Candida yeasts against azole antifungal drugs. J Mycol Med 22:173–178. https://doi.org/10.1016/j.mycmed.2012.04.004
Odds FC, Hanson MF, Davidson AD, Jacobsen MD, Wright P et al (2007) One-year prospective survey of Candida bloodstream infections in Scotland. J Med Microbiol 56:1066–1075
Omrani AS, Almaghrabi RS (2017) Complications of hematopoietic stem transplantation: fungal infections. Hematol Oncol Stem Cell Ther 10:239–244. https://doi.org/10.1016/j.hemonc.2017.05.013
Osthoff M, Wojtowicz A, Tissot F, Jørgensen C, Thiel S et al (2016) Association of lectin pathway proteins with intra-abdominal Candida infection in high-risk surgical intensive-care unit patients. A prospective cohort study within the fungal infection network of Switzerland. J Infect 72:377–385
Ostrosky-Zeichner L, Casadevall A, Galgiani JN, Odds FC, Rex JH (2016) An insight into the antifungal pipeline: selected new molecules and beyond. Nat Rev Drug Discov 9(9):719–727
Perlin DS, Rautemaa-Richardson R, Alastruey-Izquierdo A (2017) The global problem of antifungal resistance: prevalence, mechanisms, and management. Lancet Infect Dis 17:e383–e392. https://doi.org/10.1016/S1473-3099(17)30316-X
Petersen AB, Konotop G, Hanafiah NHM, Hammershøj P, Clausen MH (2016) Strategies for improving the solubility and metabolic stability of griseofulvin analogues. Eur J Med Chem 116:210–215
Pierce CG, Srinivasan A, Uppuluri P, Ramasubramanian AK, López-Ribot JL et al (2013) Antifungal therapy with an emphasis on biofilms. Curr Opin Pharmacol 13:726–730
Poulat C, Nivoix Y, Launoy A, Lutun P, Bachellier P et al (2017) Évaluation des pratiques cliniques de prescription des antifongiques systémiques coûteux. Med Mal Infect 47:382–388. https://doi.org/10.1016/j.medmal.2017.03.004
Pu S, Niu S, Zhang C, Xu X, Qin M et al (2017) Epidemiology, antifungal susceptibilities, and risk factors for invasive candidiasis from 2011 to 2013 in a teaching hospital in Southwest China. J Microbiol Immunol Infect 50:97–103. https://doi.org/10.1016/j.jmii.2015.01.005
Puia-Dumitrescu M, Smith PB (2017) Antifungal drugs in newborns and children. Pediatric Clin North Am 64:1389–1402. https://doi.org/10.1016/j.pcl.2017.08.013
Quindós G (2014) Epidemiology of candidaemia and invasive candidiasis. A changing face. Rev Iberoam Micol 31:42–48. https://doi.org/10.1016/j.riam.2013.10.001
Rajendran R, Sherry L, Nile CJ, Sherriff A, Johnson EM et al (2016) Biofilm formation is a risk factor for mortality in patients with Candida albicans bloodstream infection – Scotland, 2012–2013. Clin Microbiol Infect 22:87–93. https://doi.org/10.1016/j.cmi.2015.09.018
Raschmanová H, Weninger A, Glieder A, Kovar K, Vogl T et al (2018) Implementing CRISPR-Cas technologies in conventional and non-conventional yeasts: current state and future prospects. Biotechnol Adv 36:641–665. https://doi.org/10.1016/j.biotechadv.2018.01.006
Rautenbach M, Troskie AM, Vosloo JA (2016) Antifungal peptides: to be or not to be membrane active. Biochimie 130:132–145. https://doi.org/10.1016/j.biochi.2016.05.013
Revie NM, Iyer KR, Robbins N, Cowen LE (2018) Antifungal drug resistance: evolution, mechanisms and impact. Curr Opin Microbiol 45:70–76. https://doi.org/10.1016/j.mib.2018.02.005
Reyes-Montes MDR, Duarte-Escalante E, Martínez-Herrera E, Acosta-Altamirano G, Frías-De LMG et al (2017) Current status of the etiology of candidiasis in Mexico. Rev Iberoam Micol 34:203–210. https://doi.org/10.1016/j.riam.2017.05.001
Robbins N, Caplan T, Cowen LE (2017) Molecular evolution of antifungal drug resistance. Annu Rev Microbiol 71:753–775. https://doi.org/10.1146/annurev-micro-030117-020345
Salari S, Mousavi SAA, Hadizadeh S, Izadi A (2017) Epidemiology of dermatomycoses in Kerman province, southeast of Iran: a 10-years retrospective study (2004–2014). Microb Pathog 110:561–567. https://doi.org/10.1016/j.micpath.2017.07.043
Salci TP, Negri M, Abadio AKR, Svidzinski TIE, Kioshima ÉS (2018) Targeting Candida spp. to develop antifungal agents. Drug Discov Today 23:802–814. https://doi.org/10.1016/j.drudis.2018.01.003
Sandven P, Sandven P, Bevanger L, Digranes A, Haukland HH, Mannsåker T et al (2006) Candidemia in Norway (1991 to 2003): results from a nationwide study. J Clin Microbiol 44:1977–1981
Sanglard D (2002) Resistance of human fungal pathogens to antifungal drugs. Curr Opin Microbiol 5:379–385
Scorzoni L, Sangalli-Leite F, de Lacorte SJ, de Paula ESAC, Costa-Orlandi CB et al (2016) Searching new antifungals: the use of in vitro and in vivo methods for evaluation of natural compounds. J Microbiol Methods 123:68–78. https://doi.org/10.1016/j.mimet.2016.02.005
Scorzoni L, de Paula ESAC, Marcos CM, Assato PA, de Melo WC (2017) Antifungal therapy: new advances in the understanding and treatment of mycosis. Front Microbiol 8:1–23
Song J, Zhang S, Lu L (2018) Fungal cytochrome P450 protein Cyp51: what we can learn from its evolution, regulons and Cyp51-based azole resistance. Fungal Biol Rev 32:131–142. https://doi.org/10.1016/j.fbr.2018.05.001
Srinivasan A, Lopez-Ribot JL, Ramasubramanian AK (2014) Overcoming antifungal resistance. Drug Discov Today Technol 11:65–71
Sun Y, Meng F, Han M, Zhang X, Yu L et al (2015) Epidemiology, management, and outcome of invasive fungal disease in patients undergoing hematopoietic stem cell transplantation in China: a multicenter prospective observational study. Biol Blood Marrow Transplant 21:1117–1126
Sutcu M, Salman N, Akturk H, Dalgıc N, Turel O et al (2016) Epidemiologic and microbiologic evaluation of nosocomial infections associated with Candida spp in children: a multicenter study from Istanbul, Turkey. Am J Infect Control 44:1139–1143. https://doi.org/10.1016/j.ajic.2016.03.056
Van De Veerdonk FL, Gresnigt MS, Romani L, Netea MG, Latgé JP (2017) Aspergillus fumigatus morphology and dynamic host interactions. Nat Rev Microbiol 15:661–674. https://doi.org/10.1038/nrmicro.2017.90
Vanden Bossche H, Dromer F, Improvisi I, Lozano-Chiu M, Rex JH, Sanglard D (1998) Antifungal drug resistance in pathogenic fungi. Med Mycol 36:119–128
Varshney N, Schaekel A, Singha R, Chakraborty T, van Wijlick L et al (2015) A surprising role for the Sch9 protein kinase in chromosome segregation in Candida albicans. Genetics 199:671–674
Vicente MF, Basilio A, Cabello A, Peláez F (2003) Microbial natural products as a source of antifungals. Clin Microbiol Infect 9:15–32
Vyas VK, Barrasa MI, Fink GR (2015) A Candida albicans CRISPR system permits genetic engineering of essential genes and gene families. Sci Adv 1:e1500248
Wainwright M (2008) Some highlights in the history of fungi in medicine – a personal journey. Fungal Biol Rev 22:97–102. https://doi.org/10.1016/j.fbr.2008.11.001
Waterman GIL, Michael R (2008) Sterol 14α-demethylase cytochrome P450 (CYP51), a P450 in all biological kingdoms. Biochim Biophys Acta 1770:467–477
Wiederhold NP (2017) Antifungal resistance: current trends and future strategies to combat. Infect Drug Resist 10:249–259
Wriessnegger T, Pichler H (2013) Yeast metabolic engineering – targeting sterol metabolism and terpenoid formation. Prog Lipid Res 52:277–293. https://doi.org/10.1016/j.plipres.2013.03.001
Xie S, Shen B, Zhang C, Huang X, Zhang Y (2014) SgRNAcas9: a software package for designing CRISPR SgRNA and evaluating potential off-target cleavage sites. PLoS One 9:1–9
Acknowledgments
I profoundly thank my dear friend Prof. Dr. Vijai Kumar for inviting me to contribute to this interesting topic. I am also immensely thankful for the whole scientific community as well as editors, referees, and the whole line of people working along with the research and publication processes because without all the work it would not be possible to build such a chapter and bring it to the public.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Rodrigues, A.G. (2020). Yeast Engineering for New Antifungal Compounds: A Contextualized Overview. In: Hesham, AL., Upadhyay, R., Sharma, G., Manoharachary, C., Gupta, V. (eds) Fungal Biotechnology and Bioengineering. Fungal Biology. Springer, Cham. https://doi.org/10.1007/978-3-030-41870-0_2
Download citation
DOI: https://doi.org/10.1007/978-3-030-41870-0_2
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-41869-4
Online ISBN: 978-3-030-41870-0
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)